Moreover, we identify dysregulated AKT-FOXO3 signaling as a key resistance mechanism in selinexor-resistant cells and, accordingly, that the rational combination with MK-2206 overcomes this resistance, as shown in non-responders using ex vivo-treated patient-derived AML samples and in AML cell lines. The gene discussed is AKT1; the disease is acute myeloid leukemia.